348 related articles for article (PubMed ID: 23797151)
1. Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Maj-Hes A; Medioni J; Scotte F; Schmidinger M; Kramer G; Combe P; Gornadha Y; Elaidi R; Oudard S
Oncology; 2013; 85(1):8-13. PubMed ID: 23797151
[TBL] [Abstract][Full Text] [Related]
2. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium.
Harshman LC; Kroeger N; Rha SY; Donskov F; Wood L; Tantravahi SK; Vaishampayan U; Rini BI; Knox J; North S; Ernst S; Yuasa T; Srinivas S; Pal S; Heng DY; Choueiri TK
Clin Genitourin Cancer; 2014 Oct; 12(5):335-40. PubMed ID: 24787966
[TBL] [Abstract][Full Text] [Related]
3. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI.
Park K; Lee JL; Park I; Park S; Ahn Y; Ahn JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Med Oncol; 2012 Dec; 29(5):3291-7. PubMed ID: 22460837
[TBL] [Abstract][Full Text] [Related]
7. Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Weikert S; Kempkensteffen C; Busch J; Johannsen M; Grünwald V; Zimmermann K; Flörcken A; Westermann J; Weinkauf L; Miller K; Keilholz U
World J Urol; 2013 Aug; 31(4):805-9. PubMed ID: 21512806
[TBL] [Abstract][Full Text] [Related]
8. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
[TBL] [Abstract][Full Text] [Related]
10. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
11. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
[TBL] [Abstract][Full Text] [Related]
12. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
13. Everolimus vs. temsirolimus for advanced renal cell carcinoma: use and use of resources in the US Oncology Network.
Vogelzang NJ; Bhor M; Liu Z; Dhanda R; Hutson TE
Clin Genitourin Cancer; 2013 Jun; 11(2):115-20. PubMed ID: 23063578
[TBL] [Abstract][Full Text] [Related]
14. Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.
Pal SK; Figlin RA
Target Oncol; 2011 Mar; 6(1):5-16. PubMed ID: 21484496
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
16. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
17. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
18. Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.
Kuroshima K; Yoshino H; Okamura S; Tsuruda M; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
Cancer Sci; 2020 May; 111(5):1607-1618. PubMed ID: 32232883
[TBL] [Abstract][Full Text] [Related]
19. mTOR inhibitors in advanced renal cell carcinoma.
Voss MH; Molina AM; Motzer RJ
Hematol Oncol Clin North Am; 2011 Aug; 25(4):835-52. PubMed ID: 21763970
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
